A Q&A with Thomas Müller, adaptive licensing sceptic from Germany’s health technology assessment body, the G-BA
This article was originally published in SRA
Executive Summary
German health technology assessor Thomas Müller put the cat among the pigeons recently when he suggested that adaptive licensing – under which certain new drugs would be approved earlier on in the development process than at present and on the basis of less evidence – could be perceived as a lowering of standards at the European Medicines Agency.
You may also be interested in...
Five New EU Filings Leave Starting Blocks at EMA
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
Zyntgelo Advocates Accuse UK HTA Body Of Failing To 'Understand Patients' Lived Experience’
The UK Thalassaemia Society says that HTA body NICE fails to properly incorporate patient experiences into its decision making and that its patient engagement processes need reform. The marketing of Zynteglo, the gene therapy from bluebird bio for which the group is advocating, has just been temporarily suspended.
EU Fast-Track Fail For Another BMS CAR-T Cell Therapy
Bristol Myers Squibb says it is common for cell and gene therapies to revert to the standard timetable as ide-cel follows liso-cel in losing its accelerated assessment status at the European Medicines Agency. Separately, the company has discontinued development of orva-cel, a CAR-T cell therapy that was earlier in the development pipeline.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: